NASDAQ:AKTX

Akari Therapeutics Stock Insider Trading

etoro logo Buy AKTX
*Your capital is at risk
$14.99
+0.355 (+2.43%)
At Close: Jun 03, 2026

Akari Therapeutics Stock Insider Power

Based on the 100 latest insides trades, we have calculated the insider power to be positive at 100.00. In total, the insiders bought 25.2M and sold 0 AKTX shares in the last 100 trades. The insider score can be negative despite buy/sell ratio being positive. The score focuses on the quality of the trades.

Insider Power

(Last 100 transactions)
100.00
Buy 25.2M shares
Sell 0 shares
100% Buy Activity
Weak Negative Correlation

No Significant Signals

No statistically significant buy or sell signals detected in recent insider data.

Historical Insider Trades

Date Type Person Role Amount
Mar 20, 2025
Buy
Stock Option (Right to Buy)
A-Award
Hombeck Torsten
CFO
C-Suite Officer 300 000
Value: $450.0K
Mar 20, 2025
Buy
Stock Option (Right to Buy)
A-Award
Prudo-chlebosz Raymond
Director
Director 175 000
Value: $262.5K
Mar 20, 2025
Buy
Stock Option (Right to Buy)
A-Award
Prudo-chlebosz Raymond
Director
Director 225 000
Value: $337.5K
Mar 20, 2025
Buy
Stock Option (Right to Buy)
A-Award
Patel Sandip I
Director
Director 175 000
Value: $262.5K
Mar 20, 2025
Buy
Stock Option (Right to Buy)
A-Award
Patel Sandip I
Director
Director 225 000
Value: $337.5K
Mar 20, 2025
Buy
Stock Option (Right to Buy)
A-Award
Patel Samir Rashmikant
Director
Director 175 000
Value: $262.5K
Mar 20, 2025
Buy
Stock Option (Right to Buy)
A-Award
Patel Samir Rashmikant
Director
Director 225 000
Value: $337.5K
Mar 20, 2025
Buy
Stock Option (Right to Buy)
A-Award
Bazemore Robert B
Director
Director 175 000
Value: $262.5K
Mar 20, 2025
Buy
Stock Option (Right to Buy)
A-Award
Bazemore Robert B
Director
Director 225 000
Value: $337.5K
Mar 20, 2025
Buy
Stock Option (Right to Buy)
A-Award
Neal James R
Director
Director 175 000
Value: $262.5K
Mar 20, 2025
Buy
Stock Option (Right to Buy)
A-Award
Neal James R
Director
Director 225 000
Value: $337.5K
Mar 06, 2025
Buy
American Depositary Shares representing Ordinary Shares
A-Award
Patel Sandip I
Director
Director 44 642
Value: $50.0K
Mar 06, 2025
Buy
Series A Warrants (Right to Buy)
A-Award
Patel Sandip I
Director
Director 44 642
Value: $38.8K
Mar 06, 2025
Buy
Series B Warrants (Right to Buy)
A-Award
Patel Sandip I
Director
Director 44 642
Value: $38.8K
Mar 06, 2025
Buy
Series B Warrants (Right to Buy)
A-Award
Patel Sandip I
Director
Director 44 642
Value: $38.8K
Mar 06, 2025
Buy
Series A Warrants (Right to Buy)
A-Award
Patel Sandip I
Director
Director 44 642
Value: $38.8K
Mar 06, 2025
Buy
American Depositary Shares representing Ordinary Shares
A-Award
Patel Sandip I
Director
Director 44 642
Value: $50.0K
Mar 06, 2025
Buy
Series B Warrants (Right to Buy)
A-Award
Bazemore Robert B
Director
Director 44 642
Value: $38.8K
Mar 06, 2025
Buy
Series A Warrants (Right to Buy)
A-Award
Bazemore Robert B
Director
Director 44 642
Value: $38.8K
Mar 06, 2025
Buy
American Depositary Shares representing Ordinary Shares
A-Award
Bazemore Robert B
Director
Director 44 642
Value: $50.0K
Mar 06, 2025
Buy
Series B Warrants (Right to Buy)
A-Award
Neal James R
Director
Director 4 464
Value: $4K
Mar 06, 2025
Buy
Series A Warrants (Right to Buy)
A-Award
Neal James R
Director
Director 4 464
Value: $4K
Mar 06, 2025
Buy
American Depositary Shares representing Ordinary Shares
A-Award
Neal James R
Director
Director 4 464
Value: $5K
Mar 06, 2025
Buy
Series B Warrants (Right to Buy)
A-Award
Patel Samir Rashmikant
Director
Director 406 250
Value: $353.4K
Mar 06, 2025
Buy
Series A Warrants (Right to Buy)
A-Award
Patel Samir Rashmikant
Director
Director 406 250
Value: $353.4K

About Insider Power

Insider Power is a proprietary algorithm developed by StockInvest.us to evaluate the significance of insider transactions. The calculation considers the size, type, and timing of transactions, as well as the insider’s role within the company.

It is important to note that, in general, there is little to no correlation between insider transactions and short-term stock price movements. In one of our studies, only 0.22%* of stocks with insider activity showed a measurable correlation — and even then, it was unclear whether the effect was caused by insider actions or simply by the stock’s broader trend.

While our algorithms are designed to highlight potentially meaningful signals, these cannot be regarded as statistically significant on their own. Insider trading activity should therefore be seen as informative rather than as direct trading guidance. The Insider Power metric was created to present this information in a clearer and more accessible way, helping investors better understand the possible context of insider activity.

* October 6th, 2025 - Tested on 5562 stocks

Click to get the best stock tips daily for free!
ABOUT AKARI THERAPEUTICS PLC
Akari Therapeutics
Akari Therapeutics, Plc, a clinical-stage biopharmaceutical company, focuses on developing advanced therapies for autoimmune and inflammatory diseases. Its lead product candidate is nomacopan, a second-generation complement inhibitor that prevents inflammatory and prothrombotic activities, including paroxysmal nocturnal hemoglobinuria, Guillain-Barré syndrome, hematopoietic stem cell transplant-associated thrombotic microangiopathy, and bullous ...
GOLDEN STAR
Ticker Change Signal Date
LITE
$905.00
3.65% Jun 01
RUN
$12.83
15.74% May 06
GLBE
$31.61
0.569% May 05
SAP
$172.39
4.80% May 05
ADBE
$243.57
5.20% Apr 29

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE